A question of public trust

Number 16

1 January 2007 0

Recent headlines in the UK press have again put the issue of pharmaceutical company sponsorship of cancer initiatives under the spotlight, rekindling the debate about its dangers and its merits. Whenever a non-profit advocacy, patient [more]

Fast and effective?

Number 16

1 January 2007 0

EMEA’s new system for fast-tracking drugs aims to offer quicker access to promising new therapies without jeopardising essential research. Draft Guidance on the use of the new conditional marketing approval procedure will shortly be published, [more]

From plan to practice

The French Cancer plan of 2003 raised expectations among the public and patients.This article, which looks at how a key measure is being implemented in practice, was one of several stories that earned Paul Benkimoun [more]

Closing the survival gap

Number 16

1 January 2007 0

EU countries from Central and Eastern Europe are trying to close the gap with Western Europe in cancer prevalence and survival rates. In Ljubljana, politicians, experts and patients came together to debate cancer plans, political [more]

Immune no longer

Number 16

1 January 2007 0

Two patients out of 17 may not seem very impressive. But their recovery has boosted hopes that we can find ways to teach our immune systems to kill cancer cells. Download full article

UA-77507851-1